A B S T R A C T The metabolic disposition of the plasma binding protein (DBP) for vitamin D and its metabolites was studied in adult rabbits. Apo-DBP was purified from rabbit plasma and enzymatically labeled with radioiodine. The radioiodine-labeled protein retained its ability to bind vitamin D sterols and its physicochemical properties. When 125I-labeled DBP and '3II-labeled rabbit albumin were simultaneously injected intravenously, the 1251 was cleared from plasma at a faster rate (t1/2 = 1.7 d) than 131I (tl/2 = 5 d) and 125I was present in excess of 131I in kidney, liver, skeletal muscle, heart, lung, intestine, testis, and bone 1 h after injection. In contrast to DBP, 25(OH)D3 was cleared more slowly (t1/2 = 10.7 d). Compared to albumin, DBP radioactivity appeared earlier and in greater quantity in the urine ofcatheterized rabbits. Gel filtration analyses of plasma revealed most of the 1251 to elute in the position of DBP, with only small amounts in the <1,000-dalton region. In contrast, almost all of the urine 1251 eluted in this small molecular weight fraction. The molar ratio of DBP to 25(OH)D3 in normal rabbit plasma was 138/1. The extravascular pool of DBP was calculated to be 1.5-2.4 times larger than the intravascular DBP pool, and the molar replacement rate of DBP was 1,350-fold higher than that for 25(OH)D3. The plasma disappearance curves of holo-DBP, prepared either by saturating with 25(OH)D3 or by covalently linking 3,8-bromoacetoxy-25(OH)D3, were very similar to that of apo-DBP. Neuraminidase treatment of DBP did not alter its plasma survival.
INTRODUCTION
Although recognized for 20 yr (1), the human plasma binding protein (DBP)l for vitamin D and its metabolites has only recently been isolated and characterized (2) (3) (4) . It is an alpha globulin of -58,000 mol wt, containing one sterol binding site per molecule with the highest binding affinity for the vitamin D metabolites, 25-hydroxycholecalciferol [25(OH)D3] and 24,25-dihydroxycholecalciferol [24, 25(OH) 2D3 ]. This protein is now known to be physicochemically and immunologically identical to the group specific component (Gc) human plasma protein (2, 3, 5) . There is some evidence to suggest that this protein is synthesized in the liver (6, 7) and it occurs in high concentrations (6-8 ,uM) in plasma of man (5, (7) (8) (9) and rat (10, 11) , whether measured by immunoassay or by saturation analysis of plasma 25(OH)D binding capacity. When compared with the likely total content ofthe vitamin D sterols (0.1-0.2 AM) in plasma in vitamin D-sufficient mammals it is apparent that the apo-DBP is present in remarkable excess of its ligand.
The plasma concentration of DBP is unaffected by a wide variety of disorders of mineral homeostasis (5, 7, 9) and unlike the retinol-binding protein, which declines in concentration during deficiency of vitamin A (12) , the plasma level of DBP does not decrease during vitamin D deficiency. Although patients with cirrhosis and nephrotic syndrome (7) have a reduced plasma concentration of DBP, it nevertheless remains far in excess of that required to bind the normal amounts of vitamin D sterols in the blood. In analyses of over 80,000 different samples of human plasma (13) none were found where DBP (Gc) was absent, thus suggesting a vital role for this plasma protein.
To date, there is no information on the plasma turnover rate or the metabolic fate of DBP. To help define these purified rabbit plasma DBP was labeled with radioiodine and its plasma clearance and tissue accumulation were studied in rabbits. These experiments reveal that DBP, either in the apo or the holo form, is cleared quickly from plasma by a number of tissues and during this process is degraded to small molecular weight fragments. METHODS Materials. Crystalline rabbit plasma albumin, bovine serum albumin, type V, lactoperoxidase (milk, 67 U/mg protein), neuraminidase (type VIII, Clostridium perfringens, dithiothreitol, iodoacetamide, and blue dextran were purchased from Sigma Chemical Co., Dorset, England. 125lodine (carrier-free) and "3'iodine (free from reducing agents) were obtained from The Radiochemical Centre, Bucks., England. Bromoacetic acid (practical grade) and dicyclohexylcarbodiimide were obtained from Eastman Organic Chemicals Div., Eastman Kodak Co., Rochester, N. Y. Calibration proteins for determination ofmolecular weight were obtained as a kit from Boehringer Corp., East Sussex, England.
Sterol studies. 25-hydroxy [26,27-3H] cholecalciferol (25(OH) [26, 27 -3H]JD3) (9.6 Ci/mmol, The Radiochemical
Centre) was 99% pure as determined by silica gel GF254 thinlayer chromatography (14) . Unlabeled 25(OH)D3 was a gift from Hoffmann-La Roche, Basel, Switzerland, and its purity and quantity were assessed by ultraviolet spectrometry. For studies in vivo, 1.5 ml rabbit plasma was mixed with 3 i.Ci of 25(OH) [26, 27 -3H]D3 dissolved in 10 ,lI ethanol and kept at 4°C overnight. Polyacrylamide gel electrophoresis revealed >95% of the 3H to be associated with a protein in the alpha globulin region. After intravenous injection of the 25(OH)-[27,27-3H]D3 complex into rabbits, blood samples were taken at intervals for plasma analysis. These samples (1 ml) were extracted with chloroform-methanol (15) . Radioactivity was measured in the 25(OH)D3 fraction obtained by silicic acid chromatography (16) . Purification of rabbit DBP. DBP, labeled with tracer quantities of 25(OH)D[26,27-3H]D3, was isolated in pure form from 100 ml ofnormal pooled rabbit plasma by dialysis, DEAE ion-exchange column chromatography, gel filtration, on an AcA 44 column, and preparative 7% polyacrylamide gel electrophoresis. The final product was purified 175-fold relative to plasma and was judged to be homogeneous by analytical polyacrylamide gel electrophoresis (Fig. 1 ). In addition, the final preparation induced a monospecific antiserum in sheep which recognized only DBP in rabbit serum on agar gel diffusion or electrophoresis. The sheep anti-rabbit DBP antiserum did not react with DBP in human, monkey, rat, or chicken plasma. The concentration of DBP in rabbit serum was measured using the sheep anti-rabbit preparation in radial immunodiffuision assay (17) , on gels made with 1% agarose in 0.025 M sodium barbitone buffer, pH 8.6.
Labelinig of proteins vith "25I antd 131I. Purified rabbit plasma DBP and rabbit plasma albumin were labeled with 1251 and '31I, respectively by the lactoperoxidase method of Miyachi et al. (18) . After labeling with radioiodine, 0.5 ml of 0.05 M sodium phosphate buffer, pH 7.5, containing 1.0 mg potassium iodide was added. The entire incubation volume was then layered onto a 0.5 x 17-cm column of Sephadex G-50 (Pharmacia Fine Chemicals Ltd., London, England) equilibrated in 0.02 M sodium phosphate containing 0.3 M sodium chloride, pH 7.4. The column had been precoated by running through it 1 ml 0.5% bovine serum albumin in the column buffer and the void volume had been determined with blue dextran. The latter phase of the void volume was collected. Radioiodine was removed by this step, and additional analyses by polyacrylamide gel electrophoresis or gel filtration on 1 x 40-cm columns of Ultragel AcA54 (LKB, Bromma, Sweden) were carried out. Specific activities of 25-50,Ci/,ug protein were routinely obtained with this procedure. Denatured DBP was produced by treating 125I-labeled DBP in 1% sodium dodecyl sulphate and 2 mM dithiothreitol overnight at room temperature, followed by the addition of 0.02 M iodoacetamide for a further hour. More than 99% of the dialyzed product's radioactivity precipitated in the presence of cold trichloroacetic acid.
Preparation of holo-25(OH)D3-DBP. Three different approaches were taken in the studies with holo-25(OH)D3-DBP. (a) Radioiodinated apo-DBP was incubated in vitro with a twofold molar excess of unlabeled 25(OH)D3. The radiolabeled DBP, in 1.5 ml cold 0.02 M sodium phosphate, 0.15 M sodium chloride, pH 7.5, was added to the 25(OH)D3 in 10,ul ethanol and the preparation was mixed and incubated at 0°C for 2 h before injection into rabbits. Preliminary experiments with 25(OH) [26,27-3H] D3 were conducted to assess the abilities of unlabeled and 125I-labeled apo-DBP to bind this sterol. After incubation the unbound sterol was removed with dextran-coated charcoal (16) . The supernate was counted in a gamma spectrometer and extracted with chloroform-methanol (2:1, vol/vol). The chloroform phase was washed three times with water and assayed for 3H. Calculations based on the known specific activities of '251-DBP and 25(OH) [26,27-3H] D3 revealed that both preparations were capable of binding nearly equimolar amounts of the sterol.
(b) In one experiment an attempt was made to saturate plasma DBP in vivo by injecting an amount of unlabeled 25(OH)D3 equivalent to 1.5 times the molar amount of DBP in the plasma pool. The sterol was injected intravenously in propylene glycol, 10 min before the injection of holo-DBP labeled with radioiodine.
(c) A covalent holo 25(OH)D3-DBP preparation was made by a modification of an affinity labeling procedure previously described (19) . Monobromoacetic acid was distilled and the fraction of boiling point 202-204°C was collected. Tetrahydrofuran was passed over a column of neutral alumina and dried over potassium hydroxide pellets. To a stirred solution of 1.2 mg (3 ,umol) 25(OH)D3 and 2 x 166 dpm 25(OH)- [26, 27 -3H]D3 in 1.1 ml dry tetrahydrofusion at 22°C were added 0.5 mg (3.6 ,umol) bromoacetic acid in 0.5 ml of tetrahydrofuran. After 5 min 30 ,lI (0.36 ,umol) dry pyridine was added and the mixture was stirred for 2 h at 22°C. The solution was filtered through a fritted funnel and dried under nitrogen. The material was dissolved in chloroform/acetone Organs and tissues were removed within 20 min of death. They were rinsed in 0.9% sodium chloride and weighed before analyzing for radioactivity. Abdominal wall adipose tissue was excised and the entire right tibia was pulverized for a representative bone sample. Skeletal muscle was obtained from the right thigh and duodenum was used as the sample of small intestine. Gut lumenal contents were washed out before weighing and analysis of the intestinal tissue. Cytosols were prepared by homogenizing tissue (1:1, vol/wt) in cold 0.05 M Tris/HCl buffer pH 7.4 containing 0.15 M sodium chloride, 2 mM dithiothreitol and 2 mM EDTA. After centrifugation at 500 g for 10 min at 4°C the supernates were centrifuged at 100,000 g for 60 min at 40C. The particle-free supernates were stored at -200C before analysis.
In bred hooded rats (200 g) of the Dunn Nutritional Laboratory strain, given adequate diet and potassium iodide drinking water, were used in preliminary experiments to study the fate of labeled rabbit DBP.
Measurement of radioactivity. Tritium was assayed in a Packard Tri-Carb model 3375 scintillation spectrometer (Packard Instrument Co. Inc., Downers Grove, Ill.) using toluene or toluene-Triton X-100 scintillation solutions. Quenching was corrected by automatic external standardization.
Radioiodine in all the samples was analyzed in the same type of plastic counting vials and corrections were made for variation in counting efficiency, isotope decay and isotope spillover in a well-type, double-channel gamma spectrometer (ICN Instruments Division, Antwerp, Belgium). Variation in the counting efficiency for 1251 was minimal in samples from different tissues. 30 min after intravenous injection of 1251_ labeled and '3II-labeled rabbit serum albumin or 125I-labeled and 131I-labeled rabbit DBP into rabbits, the ratio of 125I to 1311 in the plasma was within 1% ofthe original value, but the ratio was reduced by factors of 0.95 in liver and 0.91 in bone. Since in all other tissues the ratio was within 2% of the preinjection value, corrections for the presence of 125I in tissue were made only for liver and bone.
Other methods. Gel filtration analyses on columns of Ultragel AcA54 and AcA44 were performed under constant pump pressure at 40C. Polyacrylamide gel-electrophoresis (20) , sodium dodecyl sulphate-polyacrylamide-gel electrophoresis (21), serum creatinine (22) and 25(OH)D binding assays (16) were performed as previously described.
Statistical analysis. The turnover data was calculated by a noncompartmental, mathematical analysis of the plasma specific radioactivity curves (23) The significance of the differences between the ratio of 125I/1311 in the tissue and the ratio of the injected material (see Table II ) was analyzed by the Student's t test.
RESULTS
Properties of rabbit plasma DBP. The final preparation of purified DBP was homogeneous when analyzed by polyacrylamide gel electrophoresis (Fig.  1) . Gel filtration analyses revealed that the 25(OH)-[26,27-3H]D3-DBP complex had eluted in a single peak with an apparent mol wt of 58,000 (Fig. 2B) . This was identical to the elution of radioactivity when the column was charged with normal rabbit plasma incubated with tracer quantities of 25(OH) [26,27- 3H]D3 ( Fig. 2A) . The purified DBP from rabbit plasma had alpha mobility on electrophoretic analyses in 7% polyacrylamide gels. The absorption spectrum of purified rabbit plasma DBP revealed maximum absorbance at 275 to 280 nm with a 280/260-nm absorption ratio of 1.20 i25I-labeling procedure. Radiolabeled material from the DBP region was also homogeneous when analyzed by 7% polyacrylamide gel electrophoresis. Since radioactivity in the void volume and small molecular weight regions increased slightly after protracted storage of i25I1labeled DBP, experiments with this protein were done within 24 h of its preparation and purification by gel filtration.
The polyacrylamide gel electrophorectic analyses of gel-filtered, radiolabeled rabbit serum albumin revealed >95% of the radioiodine to filter or migrate as a homogeneous band corresponding to that exhibited by reference albumin.
Preliminary studies in rats indicated a more rapid plasma clearance of radiolabeled rabbit DBP than albumin, and a preferential accumulation of DBP, compared to albumin, in most tissues examined. Unfortunately, the rat serum DBP has a high tendency to polymerize (11) . This consideration, and our desire to examine a homologous system, prompted our carrying out further studies in rabbits.
Plasma survival of radiolabeled proteins and 25(OH)D3. Fig. 3 presents the early disappearance of 125I-labeled DBP and 131I-labeled rabbit albumin from the plasma of a normal rabbit after the simultaneous intravenous injection of these proteins. During the first minutes, both proteins disappeared from the plasma at similar rates but a more rapid egress of DBP was apparent by 1 h after injection. At this time the mean 125I_/1311 ratio found in four rabbits was 0.95, which was significantly less (P < 0.02) than the ratio of the injected material. The curves describing the disappearance ofboth proteins were multiexponential within the first day. After a brief delay, both isotopes appeared in the urine and a greater rate of urinary excretion of 125I was observed. At 24 h, the plasma disappearance rate of DBP was clearly more rapid and only 16% of the dose remained in the vascular compartment. Over 24 h -22% of the dose of 1251 and 10% of the dose of 131I appeared in urine. The divergent rates ofplasma clearance ofthese proteins remained distinct after 48 h when only 9% of the injected DBP was present in plasma. In contrast to the behavior of these proteins, denatured DBP was cleared more rapidly with <10% of the dose re-. maining in plasma 8 h after injection (Fig. 3) .
The later phases of the plasma disappearance of the two proteins and 25(OH) [26,27-3H] Fig. 4 . The apparent plasma removal rate of the sterol was similar to those of the proteins only during the first few hours after injection (Fig. 3) Fig. 4 . Base-line plasma concentrations of DBP or 25(OH)D were almost identical to those measured during and after the experiments. Table I summarizes the analyses of the plasma survival curves.
Plasma survival of neuraminidase-treated DBP and holo-25(OH)D3-DBP. Factors which might affect the plasma clearance rate of DBP have been considered. The role of sialic acid residues in the uptake by liver of plasma proteins was shown by Ashwell and Morell (24) but we found that the presence of this residue on DBP is not essential for its normal turnover rate. Presumptive evidence for heterogeneity in purified rabbit DBP was revealed by neuraminidase treatment (3 U/ 0.1 ml in 0.1 M sodium acetate, pH 5.3, for 15 h at 37°C) of 3 ,g 1251-labeled DBP. When this preparation and 131I-labeled DBP incubated without enzyme were analyzed by polyacrylamide gel electrophoresis, a higher 1251/1311 ratio was observed in cathodal slices of the DBP band. These findings suggest that sialic acid was present in anodal portions of the DBP preparation as had been reported for human DBP (25) (26) (27) In the third experiment shown here, 4 ,tg of denatured 1251_ labeled DBP (A) was intravenously injected into a third rabbit. The plasma disappearance of trichloroacetic acidprecipitable 125I and 1311 was studied in a rabbit injected simultaneously with 125I-labeled DBP which had been treated with neuraminidase and 131I-labeled DBP which had not been exposed to this enzyme in vitro.
The plasma survival curves of these two preparations are shown in Fig. 5 . The removal of sialic acid from the "fast" electrophoretic moiety of DBP did not cause any apparent alteration in its plasma survival.
It is also possible that the turnover rate of DBP is affected by the presence or absence of 25-(OH)D3. Saturation of 1251-labeled DBP with 25(OH)D3 in vitro did not alter its rate of egress from plasma (data not presented). A similar preparation was injected 10 min after the slow intravenous injection of480 ,ug (1.2 mmol) of25(OH)D3, which was a 1.5-molar excess ofligand for the calculated intravascular pool of DBP (-50 mg or 0.8 ,umol for a 3-kg rabbit). As indicated in Fig. 6 the plasma disappearance of the 125I-labeled DBP was not substantially changed by these procedures. Plasma creatinine was not increased after this 25(OH)D3 injection but plasma 25(OH)D3 concentrations were only near DBP saturation levels (2.7 ,ug/ml) at 5 min after injection and they fell rapidly over 24 h to -0.9 ,ug/ml, reaching a level of 0.2 Ag/ml 7 d later.
The plasma survival of 125I-labeled DBP bound to the affinity labeling reagent, 3,8-bromoacetoxy-25(OH)D3, is also shown in Fig. 6 . With this preparation of ligand covalently bonded to its carrier protein, the plasma survival of 125I-labeled DBP was unchanged compared to apo-DBP. Total urinary excretion of 125I was similar to that found after injection of apo-DBP as was the presence of only low-molecular weight 125I in urine and the predominantly DBP-like 125I in gel-filtration analyses of plasma.
Properties of radiolabeled materials in plasma and urine. Analyses of plasma obtained 5 min after injection of 125I-labeled DBP revealed a gel filtration profile similar to the one shown in Fig. 2B . Samples taken at 9 d after injection revealed no less than 92% of the radioactivity to elute in a single peak with an apparent mol wt of 58,000 (Fig. 3C) . The remainder ofthe radioactivity was found in the region ofapparent mol wt < 1,000. Polyacrylamide gel electrophoresis revealed the large-molecular weight material to be DBP and the small-molecular weight material to have a net negative charge, running near the bromphenol blue front. The nature of this material has not been precisely determined but iodotyrosine, free iodine, or iodine attached to small peptides are likely possibilities. This smallsized material comprises the major portion of the radioactivity in urine collected at any time within 48 h of injection of 125I-labeled DBP (Fig. 2C) . Frequently a small amount of apparently intact 1251-labeled DBP appeared in urine samples but this never accounted for >1% of the urine radioactivity. Gel filtration profiles of urine from rabbits injected with 131I-labeled albumin revealed almost all of the 1311 to be in a small mol wt form (data not presented). Tissue, rather than plasma alone, appeared to be required for the formation of low-molecular weight 1251-material since more than 99% of 1251-labeled DBP incubated with plasma at 37°C for 1 h remained intact. In a single experiment, the low-molecular weight 125I-material was found in plasma 2 h after the injection of 1251-labeled DBP into a bilaterally nephrectomized rabbit.
After injection of 25(OH) [26, 27 -3H]D3, the major distribution of3H in plasma was observed to be associated with DBP. More than 90% ofthe radioactivity in plasma co-migrated with the binding protein on gel filtration or electrophoresis. Chromatography of lipid extracts of plasma indicated that >88% of plasma-3H ran with standard 25(OH)D3.
Tissue distribution of radiolabeled proteins. In preliminary experiments with rats, the simultaneous intravascular injection of 125I-labeled rabbit DBP and 131I-labeled rabbit albumin gave results suggesting the relatively greater accumulation of DBP in a variety of tissues at all times from 1 to 24 h after injection. Studies in one rabbit at each of several times after the simultaneous intravenous injection of 125I-labeled DBP and 131I-labeled rabbit albumin revealed an excess of 125I in many tissues shortly after injection. The significance ofthese early results was confirmed by statistical analysis of data obtained from four rabbits sacrificed 60 min after injection (Table II) . When compared to the dose ratio and the values in the 5 min plasma, the plasma DBP/albumin ratio was significantly reduced in plasma obtained 60 min after injection. The previously demonstrated difference between the plasma survival of DBP and albumin, which are proteins of similar size, suggested the possibility ofa tissue uptake of DBP that was not solely attributable to diffusion into the extracellular fluid. When tissue ratios were calculated on the basis of the total amount of each isotope administered, a significant excess of 125I was found in all tissues examined except adipose tissue. Highest ratios were found in kidney, intestine, and muscle.
When corrected for extracellular fluid contamination, the calculated organ distribution of 125I-labeled DBP still revealed highest accumulations in kidney, liver, and skeletal muscle (Table III) . Four rabbits that had received the radiolabeled proteins 24 h earlier were also sacrificed. At this time the tissue data revealed 125I accumulation to be increased in bone and adipose tissue compared to the 1-h data. When considered as the amount of 1251 accumulated per gram wet weight oftissue, kidney was the most efficient extractor and high concentrations were also noted in lung, liver, and heart.
Properties of radiolabeled material in tissue cytosols. Cytosols from tissues ofone rabbit sacrificed Four rabbits were sacrificed at each period. The amount of 125I present in the tissues was corrected for the amount present in contaminating plasma and extracellular fluid (based on the 131I content of individual tissues and the ratio of'25I to 131I in plasma). Plasma volumes of each rabbit were calculated from the degree of dilution of injected labeled proteins in plasma taken at 5 min after injection.
* Assumes skeletal muscle constitutes 35% of body weight. t Assumes adipose tissue constitutes 15% of body weight. § Assumes one tibia constitutes 5% of total skeletal weight.
60 min after the simultaneous injection of 1251-labeled DBP and 135I-labeled albumin, were analyzed on gel filtration columns (Fig. 7) . Radioactivity in plasma was almost entirely in the elution volumes corresponding to these proteins but a small amount of isotope (1.7-2.2% of total radioactivity eluted) formed a low-molecular weight (<1,000) peak (Fig. 7A) . In tissue cytosols, the 125I in the small-molecular weight peak comprised a higher percentage of the total 125I eluted (5-25%) than it did in plasma. Although diffusion of low-molecular weight material into extravascular fluid could explain its exaggerated presence compared with plasma, a comparison of the percentages of total column radioactivity in low-molecular weight form revealed a higher proportion of 1251 to 131I in most instances. Analysis of muscle cytosol is shown in Fig. 7B and the 125I profile of kidney cytosol in Fig. 7C . The statistical significance of the relatively higher tissue accumulations of DBP (Table II) was not altered by subtraction of the lowmolecular weight 1251 components in cytosols.
In all cytosols examined, another feature consistently observed was the presence of high-molecular weight, 125I-labeled material eluting at or near the void volume and extending into the volume of DBP elution (Figs. 7B and 7C ). The nature of this material was studied in several cytosols containing sufficient radioactivity for analysis by sodium dodecyl sulphatepolyacrylamide gel electrophoresis (liver, heart, kidney, and lung). In each instance the high-molecular weight 1251 was not found in slices of these gels and radioactivity was present only in positions characteristic of DBP and free 1251. Most plasma samples from rabbits injected with radiolabeled DBP were free of the high-molecular weight material but small amounts were seen in samples from hemolyzed blood. The exact nature of the high-molecular weight radioactivity in such plasma was not determined.
DISCUSSION
The studies presented here show that rabbit plasma DBP can be labeled with radioiodine without causing significant alterations to its sterol-binding ability or physicochemical characteristics. Labeled DBP retained both its ability to bind 3H-labeled 25(OH)D3 in vitro as well as the electrophoretic and gel filtration behavior of the native protein. Since purposefully denatured labeled DBP was cleared much more rapidly from plasma after injection into rabbits, the more protracted plasma survival of native DBP apparently depends on the retention of its tertiary conformation. The large amount of endogenous plasma DBP prevented verification of the 125I-labeled DBP plasma survival data by immunoquantitation after its injection. However, the plasma survival of 14C-labeled DBP prepared by the method of Dottavio-Martin and Ravel (28) Vitamin D Plasma Binding Protein FRACTION NUMBER FIGURE 7 Gel filtration of plasma and tissue cytosols obtained 1 h after the simultaneous intravenous injection of 125I-labeled DBP and 131I-labeled rabbit serum albumin (RSA).
Analyses were carried out as described for Fig. 2 (Table I ). Since the normal rabbit plasma molar ratio of DBP to 25(OH)D3 is 138:1, the metabolic turnover of plasma DBP is almost 10 times that of 25(OH)D3. The recognition of the faster turnover of plasma proteins in smaller animals (29) does not substantially detract from the conclusion that the transport capacity (concentration x turnover rate) of DBP in mammals is remarkably high.
Experiments with 3H-labeled 25(OH)D3 indicated that as in man, this sterol has an apparently long plasma survival (t12 = 10.7 d) (Fig. 4) (Figs. 3 and 4) . It is also possible that the dissociation of 25(OH)D3 from DBP might occur in the extracellular compartment. The experiments with apo and holo-25(OH)D3 DBP preparations (Figs. 4 and 6) indicated a very similar plasma clearance of these materials and therefore do not suggest a different clearing mechanism for these forms of DBP. Since we did not examine the relative tissue accumulations of apo-DBP and holo-DBP, a subtle difference in their tissue uptake remains a possibility. Our experiments with 125I1-labeled DBP covalently bonded to 3,8-bromoacetoxy-25(OH)D3 (Fig. 6 ) support the data obtained with in vivo and in vitro saturation of 1251-labeled DBP, but in vivo hydrolysis of the sterol ester may have occurred.
A substantial metabolism ofplasma proteins is recognized to occur in liver, kidney, and intestine (35) . Experiments with neuraminidase-treated DBP (Fig. 5) revealed that this plasma protein is not likely cleared by binding to hepatic receptors that recognize galactose residues after terminal sialic residues are removed (24) . Since (36) (37) (38) . Our experiments in vivo do not provide direct evidence for cellular association or uptake of DBP, and further studies are required to examine this possibility. It is of interest, however, that a cellular protein is recognized to bind DBP (39) (40) (41) and that DBP complexed to this protein has been observed in cytosols from well-washed, cultured fibroblasts (41), well-perfused kidney (42) , in well-washed kidney subcellular fractions (42, 43) and in well-washed, cultured bone cells (44) . Others, however, have not observed the complexing of DBP by extracts from well-washed cells cultured without serum (39) . Recent evidence has been presented that the cellular DBP binding protein is actin. This provocative finding has yet to be explored, but does not guarantee an intracellular disposition of DBP because DBP might function to scavenge actin released into the circulation (45) . The metabolic pathway for vitamin D implicates many tissues in its formation, transformation, and biological action. Vitamin D itself and its potent metabolite, 1,25(OH)2D3, for example, are recognized to have plasma clearance rates and tissue distributions which are distinct from those of 25(OH)D3 (30, (46) (47) (48) . It is therefore difficult to present a unified hypothesis whereby DBP, the only specific binding protein for cholecalciferol sterols in mammalian plasma, plays a delivery function for all these sterols. Cholecalciferol and 1,25(OH)2D3 are bound by DBP with lower affinity than 25(OH)D3 (2) and probably have additional mechanisms for their tissue delivery. The hepatic and adipose tissue accumulation of vitamin D may derive from the relatively greater association ofcholecalciferol to plasma lipoproteins (49) . The solubility of the more polar metabolite, 1,25(OH)2D3 may be such that at its usual plasma concentration (30 pg/ml) it is more available in the free form for uptake by target tissues for association with their high-affinity, soluble intracellular receptors (50) (51) (52) (53) .
Since the major sterol that is most avidly bound to mammalian plasma DBP is 25(OH)D3, it is appropriate to consider the biological significance of it having a plasma transport protein of high capacity which turns over rapidly. For the transformation of 25(OH)D3 to other metabolic forms, such a transport system would guarantee a continuing supply of substrate, even when circulating levels of 25(OH)D3 are low (54) , during which time DBP levels are unchanged (7) . This interpretation, however, would only be attractive if carriermediated delivery of 25(OH)D3 occurs. The rapid replacement of DBP with newly synthesized apo-DBP might also protect cells against excessive accumulation of 25(OH)D3 by ensuring the cellular egress of unutilized 25(OH)D3, away from 1,25-(OH)2D3 receptor sites. A precise definition of the biological role of DBP, however, shall require further studies of the tissue disposition of this protein.
